Erlotinib (183321-74-6) pauta - Tagata gaosi oloa gaosi oloa
AASraw gaosia Cannabidiol (CBD) paʻu ma Hemp Taua Suauʻu tele!

Erlotinib

fua faatatau: Category:

O le Erlotinib Powder, na faʻatau atu i lalo ole igoa Tarceva faʻatasi ai ma isi, o se vailaʻau na faʻaaoga e togafitia ai le kanesa laiti ole sela (NSCLC) ma le kanesa pancreatic. Faʻapitoa lava faʻaaogaina mo NSCLC ma fesuiaʻiga i le epidermal tuputupu ae mea taliaina (EGFR) - a le o le exon 19 soloia (del19) poʻo le exon 21 (L858R) sui suiga - lea na salalau atu i isi vaega o le tino.

Faamatalaga oloa

Tulaga Autu

Igoa oloa Efuefu Erlotinib
Numera CAS 183321-74-6
Faiga Faʻavae Molecular C22H23N3O4
Fua Faatatau o le Umi 393.443
Synonyms CP-358774;

OSI774;

Erlotinib paula leai se faʻavae nofoaga;

183321-74-6.

Faʻaaliga Paʻepaʻe i le paʻu paʻepaʻe paʻepaʻe paʻepaʻe
Teuina ma Taulimaina Faʻamago, pogisa ma i le 0 - 4 C mo se taimi puʻupuʻu (aso i vaiaso) poʻo le -20 C mo se taimi umi (masina i tausaga).

 

Erlotinib Powder Faʻamatalaga

Erlotinib paula, faʻatau atu i lalo o le igoa igoa Tarceva faʻatasi ai ma isi, o se vailaʻau faʻaaoga e togafitia ai le laʻititi sela mama kanesa (NSCLC) ma pancreatic kanesa. Faʻapitoa lava faʻaaogaina mo NSCLC ma fesuiaʻiga i le epidermal tuputupu ae mea taliaina (EGFR) - a le o le exon 19 soloia (del19) poʻo le exon 21 (L858R) sui suiga - lea na salalau atu i isi vaega o le tino. E ave e le gutu.

Erlotinib efuefu o se quinazoline mafuaʻaga ma antineoplastic meatotino. O le tauvaga ma le adenosine triphosphate, o le erlotinib paula e mafai ona fusifusia i le vaega o le intracellular catalytic o le epidermal tuputupu ae o le receptor (EGFR) tyrosine kinase, ma suia ai le taofiofia o le EGFR phosphorylasi ma poloka ai faʻailoga suiga o gaioiga ma tumigenic aafiaga e fesoʻotaʻi ma le faʻaolaina EGFR.

Na faʻamaonia le pauta Erlotinib mo le faʻaogaina o vailaʻau i le Iunaite Setete i le 2004. O loʻo i luga o le Lisi o Mea Taua Vailaʻau a le Lalolagi Faʻalapotopotoga a le Lalolagi, o loʻo lisiina ai vailaau e sili ona saogalemu ma aoga e manaʻomia i se faiga faʻasoifua maloloina.

 

Erlotinib Powder Faʻavae o gaioiga

Erlotinib efuefu o se epidermal tuputupu aʻe mafua receptor taofiofia (EGFR taofiofia). O le vailaʻau e mulimuli Iressa (gefitinib), o le muamua vailaʻau o lenei ituaiga.

Erlotinib efuefu faʻapitoa faʻatutuina le epidermal tuputupu ae mea taliaina (EGFR) tyrosine kinase, lea e sili ona faʻaalia ma faʻasolosolo taimi uma i ituaiga eseese o kanesa. E fusifusia i se suiga suiga i le adenosine triphosphate (ATP) noataga nofoaga o le receptor. Mo le faʻailoga e tuʻuina atu, lua molimoli EGFR manaʻomia e o mai faʻatasi e fausia ai se homodimer.

O mea ia e faʻaaoga ai le molemole o le ATP e fefaʻatauaʻi ai le isi i luga o toega o le tyrosine, e maua mai ai le toega o le phosphotyrosine, faʻapipiʻiina ai polotini e fusifusia ai le phosphotyrosine i le EGFR e faʻaputuputu ai polotini poloka e faʻasolosolo ai faʻailoga o le tino i le vaega o le tino poʻo le faʻaaogaina o isi sela sela. A o le erlotinib paula e fusifusia i le EGFR, faʻavaeina o le phosphotyrosine residues i le EGFR e le mafai ma o le faʻailoga cascades e le amataina.

O le Erlotinib powder o le tyrosine kinase receptor inhibitor o loʻo faʻaaogaina i le togafiti o le alualu i luma poʻo le metastatic pancreatic poʻo le le laʻititi sela kanesa kanesa. Erlotinib paula togafitiga e fesoʻotaʻi ma siʻitia maualuga i luga o le serum aminotransferase tulaga i le taimi o togafitiga ma seasea taimi o falemaʻi e manino tiga matuia ate.

 

Erlotinib Powder Talosaga 

Erlotinib efuefu o se mafai ona suia muamua-augatupulaga receptor tyrosine kinase taofi (faʻatasi ai ma Gefitinib) galue muamua i luga o le epidermal tuputupu ae vaega (EGFR), o se sui o le ErbB receptor aiga. E faʻafesoʻotaʻi e le vailaʻau le ituaiga vao ma le suiga o le EGFR. E mafai e le aiga o ErbB ona fausia ni homodimers poʻo heterodimers, e masani ona aʻafia i aafiaga o le tafe o le vai ma faʻafitauli o le tele o ituaiga kanesa na suʻesuʻeina i tagata. Receptor tyrosine kinase inisetiute (TKI) puipuia le phosphorylation o latou substrate i le sela faailo auala. EGFR masani ona faia se sao i le tele o sela feʻaveaʻi, aofia ai le vavaeʻesega, faʻateleina, ma angiogenesis, o na mea uma o faʻailoga o le kanesa.

EGFR suiga i le NSCLC e masani lava o se faʻagaoioia suiga. Nisi uiga onosaʻi na mafua ai le iai o suiga EGFR sili ono aofia ai leai talaʻaga o le ulaula faʻamaonia adenocarcinoma e histologic auiliiliga, Asia ituaiga, ma fafine itupa. Maualuga suiga i le EGFR masani ona tupu, o lenei tusitusiga o loʻo faʻamatalaina i lalo.

 

Erlotinib Powder Itu Itu & Lapataiga

O itu nei e masani ona aoga mo tagata mamaʻi e ave le Erlotinib Powder:

▪ Faanatinati

▪ Manava

▪ Le lelei le manao

▪ Le lavava

▪ Manava le manava

▪ Maua

▪ Faanoi ma puaʻi

 

O nei aʻafiaga e le masani ai aʻafiaga o tagata mamaʻi o loʻo mauaina le Erlotinib Powder:

▪ Siama

▪ Ogaoga o le gutu

▪ O le mageso

▪ Paʻu mago

▪ Faasoesa i mata

▪ Paʻu o le manava

 

E le o aʻafiaga uma e lisi atu i luga. Nisi e seasea (tupu i lalo ifo o le 10% o tagata mamaʻi) e le o lisiina iinei. Peitaʻi, e tatau ona e faʻailoa i taimi uma lau auaunaga faʻasoifua maloloina pe a fai e te maua se faʻailoga e le masani ai.

 

Tusitaiala

[1] Gao JW, Zhan P, Qiu XY, Jin JJ, Lv TF, Song Y. Erlotinib-faʻalua faʻatulagaina togafitiga faʻasolosolo faʻatasi ma le erlotinib paʻu na o ia lava na togafitia i luma le o ni tamaʻi sela laʻititi pulea tofotofoga. Oncotarget 24 Me 2017; 31 (8): 42-73258. faia: 73270 / oncotarget.10.18632. eCollection 18319 Sep 2017. Toe iloilo. PubMed PMID: 22; PubMed Central PMCID: PMC29069867.

[2] Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T , Yang JC. Gefitinib poʻo Erlotinib paʻu vs Chemotherapy mo le EGFR Mutation-Positive Lung Cancer: Tagata Taʻitoʻatasi Patient Data Meta-Suʻesuʻega o le Aotelega o le Faʻaola. J Natl Kanesa Inst. 2017 Jun 1; 109 (6). faia: 10.1093 / jnci / djw279. Iloiloga PubMed PMID: 28376144.

[3] Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J. Faʻatusatusaga o gefitinib, erlotinib paʻu ma afatinib i le laʻititi kanesa kanesa mama: O se meta-auiliiliga. Int J Kanesa. 2017 Jun 15; 140 (12): 2805-2819. faia: 10.1002 / ijc.30691. Epub 2017 Mati 27. Toe iloiloga. PubMed PMID: 28295308.

[4] "Erlotinib paula (Tarceva) Faʻaaoga I le taimi o le Maitaga". Drugs.com. 1 Novema 2019. Toe aumai 23 Tesema 2019.

[5] "Erlotinib efuefu Monograp mo Polofesa". Drugs.com. Toe aumai 12 Novema 2019.

[6] "Tarceva- erlotinib pauka hydrochloride laupapa". Aso Taʻitasi 12 Tesema 2018. Toe aumai 23 Tesema 2019.

[7] "Afifi Faʻamaonia Vailaʻau: Tarceva (Erlotinib paʻu) NDA # 021743". US Taumafa ma Vailaau Faʻafoeina (FDA). 28 Mati 2005. Toe aumai 23 Tesema 2019.

[8] Raymond E, Faivre S, Armand JP (2000). "Epidermal tuputupu ae vaega taliaina receptor tyrosine kinase o se sini mo anticancer togafitiga". Fualaʻau. 60 Faʻaopopo 1: 15–23, talanoaga 41–2. faia: 10.2165 / 00003495-200060001-00002. PMID 11129168. S2CID 10555942.